Bone Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Chordoma (18)

Giant Cell Tumor of Bone (5)

Tenosynovial Giant Cell Tumor (3)

Chordoma (18)

Giant Cell Tumor of Bone (5)

Tenosynovial Giant Cell Tumor (3)

›

No biomarker	Giant Cell Tumor of Bone	No biomarker	Giant Cell Tumor of Bone	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
No biomarker	Chordoma	No biomarker	Chordoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
TMB-H	Chordoma	TMB-H	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
EGFR expression	Chordoma	EGFR expression	Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
MSI-H/dMMR	Chordoma	MSI-H/dMMR	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
SMARCB1 negative	Chordoma	SMARCB1 negative	Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
PIK3CA amplification	Chordoma	PIK3CA amplification	Chordoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PIK3CA M1043I	Chordoma	PIK3CA M1043I	Chordoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4
COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4
SMARCB1 deletion	Chordoma	SMARCB1 deletion	Chordoma	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
AXL underexpression	Chordoma	AXL underexpression	Chordoma	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
STK33 underexpression	Chordoma	STK33 underexpression	Chordoma	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
PTEN deletion	Chordoma	PTEN deletion	Chordoma	PDGFR inhibitor Resistant: D – Preclinical PDGFR inhibitor Resistant : D	PDGFR inhibitor Resistant: D – Preclinical PDGFR inhibitor Resistant : D
PTEN deletion	Chordoma	PTEN deletion	Chordoma	PDGFR inhibitor + HDAC inhibitor Sensitive: D – Preclinical PDGFR inhibitor + HDAC inhibitor Sensitive : D	PDGFR inhibitor + HDAC inhibitor Sensitive: D – Preclinical PDGFR inhibitor + HDAC inhibitor Sensitive : D
PBRM1 mutation	Chordoma	PBRM1 mutation	Chordoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D

Bone Cancer

Associations(23)

Associations
(23)